Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis

Table 1

Main characteristics of the eligible publications.

First author	Country	Age	Stage	Antibody	Sources of antibody	Staining	Cutoff values (IHC)	Cancer	Clinical features	Survival-MA
								Total (E+ %)
Ong et al. [42]	Singapore	NA	1–4	Anti-SOX2	Clone 57CT23.3.4; Abcam, Cambridge, MA	Cytoplasm	10%	310 (NA)	No	CSS
Neumann et al. [41]	Germany	66.5	NA	Anti-SOX2	Clone D6D9, cell Signaling technology, Danvers, MA	Nuclei	10%	114 (21.1%)	Yes	NA
Han et al. [40]	China	NA	NA	Anti-SOX2	Epitomics	NA	NA	44 (20.5%)	Yes	NA
Lee et al. [39]	Korea	NA	1–4	Anti-SOX2	Abcam, Cambridge, UK	Nuclei	5%	110 (17.3%)	Yes	NA
Liu et al. [43]	China	NA	1–4	Anti-SOX2	Cell Signaling Technology, Inc	Nuclei	≥2 scores	67 (22.4%)	Yes	NA
Ma et al. [38]	China	65	1–4	Anti-SOX2	ab75485, Abcam, Cambridge, MA	NA	>1.40	89 (50.6%)	Yes	NA
Raghoebir et al. [37]	The Netherlands	NA	NA	Anti-SOX2	Immune systems	Nuclei	5%	135 (20.7%)	Yes	NA
Lundberg et al. [23]	Sweden	NA	1–4	Anti-SOX2	Abcam, Cambridge, UK	Nuclei	NA	441 (10.7%)	Yes	CSS
Yan et al. [36]	China	65	3–4	Anti-SOX2	Abcam	NA	2.5	280 (41.8%)	Yes	NA
Miller et al. [24]	Australia	66.7	3	Anti-SOX2	EPR3131; Abcam cell Signaling Technology, Danvers	Nuclei	NA	104 (18.3%)	Yes	CSS, OS
Zheng et al. [35]	China	NA	1–4	Anti-SOX2	Mass cat. no. 636675, EMD Millipore	NA	NA	47 (80.9%)	Yes	NA
Han et al. [44]	Korea	59.8	3	Anti-SOX2	Billerica, MA, USA	NA	≥1 score	164 (82.3%)	No	DFS
Li et al. [34]	China	NA	1–4	Anti-SOX2	#ab92494	NA	NA	432 (NA)	No	OS

NA: not applicable; IHC: immunohistochemistry; E+: positive/high expression; MA: multivariate Cox analysis; DFS: disease-free survival; OS: overall survival; CSS: cancer-specific survival.